THERAPEUTIC STRATEGIES FOR THE PREVENTION AND TREATMENT OF PREECLAMPSIA
Issue:
3
Year:
2017
In conditions accompanied by an increase in the volume of circulating fluid (sodium-dependent hypertension, preeclampsia), there are elevated plasma concentrations of one of the key endogenous digitalis-like factors of marinobufagenin. Clinical trials investigate the efficacy of antibodies to digitalis-like substances in the treatment of preeclampsia.
Keywords:
obstetrics and gynecology
preeclampsia
intrauterine growth restriction syndrome
prevention
treatment
References:
- Glushakov R.I., Proshin S.N., Tapil'skaja N.I. Rol' tireoidnyh gormonov v reguljatsii angiogeneza, kletochnoj proliferatsii i migratsii // Geny i kletki. – 2011; 6 (4): 26–33.
- Proshin S.N., Glushakov R.I., Shabanov P.D. i dr. Znachenie ekspressii TLR-retseptorov dlja vybora farmakologicheskoj korrektsii patologii shejki matki i endometrija // Geny i kletki. – 2011; 6 (1): 91–7.
- Reznik V.A. Vazoaktivnye faktory v patogeneze preeklampsii // Arterial'naja gipertenzija. – 2006; 12 (1):22–31.
- Rjazanova O.V., Aleksandrovich. Ju.S., Shifman E.M. i dr. Sovremennye aspekty terapii matochnyh krovotechenij pri predlezhanii platsenty // Pediatrija. SPb. – 2016; 7 (3): 117–27.
- Tapil'skaja N.I., Karpeev S.A., Kuznetsova I.V. Hronicheskij endometrit – subklinicheskoe vospalitel'noe zabolevanie organov malogo taza // Ginekologija. – 2014; 16 (1): 104–9.
- Averina I., Tapilskaya N., Reznik V. et al. Endogenous Na/K-ATPase inhibitors in patients with preeclampsia // Cellular and Molecular Biology. – 2006; 52 (8): 19-23.
- Bhargava S., Tyagi S. C. Nutriepigenetic regulation by folate-homocysteine-methionine axis: a review // Mol. Cell. Biochem. – 2014; 387: 55–61.
- Bokslag A., van Weissenbruch M., Mol B. et al. Preeclampsia; short and long-term consequences for mother and neonate // Early Hum. Dev. – 2016; 102: 47–50.
- Conrad K. G-Protein-coupled receptors as potential drug candidates in preeclampsia: targeting the relaxin/insulin-like family peptide receptor 1 for treatment and prevention // Hum. Reprod. Update. – 2016; 22 (5): 647–64.
- Costa M. Preeclampsia: Reflections on How to Counsel About Preventing Recurrence // J. Obstet. Gynaecol. Can. – 2015; 37 (10): 887–93.
- Dodd J., McLeod A., Windrim R. et al. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction // Cochrane Database Syst. Rev. – 2013; 7: CD006780.
- Fedorova O., Kashkin V., Bagrov A. et al. Interaction of digibind with endogenous cardiotonic steroids from preeclamptic placentae // J. Hypertens. – 2010; 28 (2): 361–6.
- Fedorova O., Kolodkin N., Agalakova N. et al. Marinobufagenin, and endogenous a-1 sodium pump ligand, in hypertensive Dahl salt-sensitive rats // Hypertension. – 2001; 37 (2): 462–6.
- Fedorova O., Lakatta E., Bagrov A. Differential effects of acute NaCl loading on endogenous ouabain like and marinobufagenin like ligands of the sodium pump in Dahl hypertensive rats // Circulation. – 2000; 102: 3009–14.
- Fedorova O., Simbirtsev A., Kolodkin N. et al. Monoclonal antibody to an endogenous bufadienolide, marinobufagenin, reverses preeclampsia-induced Na/K-ATPase inhibition and lowers blood pressure in NaCl-sensitive hypertension // J. Hypertens. – 2008; 26 (12): 2414–25.
- Ganzevoort W., Alfirevic Z., von Dadelszen P. et al. STRIDER: Sildenafil Therapy In Dismal prognosis Early-onset intrauterine growth Restriction – a protocol for a systematic review with individual participant data and aggregate data meta-analysis and trial sequential analysis // Syst Rev. – 2014; 3: 23.
- Gonick H., Dring Y., Vaziri N. et al. Simultaneous measurement of marinobufegenin, oubain and hypertension associated protein in various disease state // Clin. Exp. Hypertens. – 1998; 20: 617–27.
- Henderson J., Whitlock E., O'Conner E. et al. Low-Dose Aspirin for the Prevention of Morbidity and Mortality From Preeclampsia: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014. Report No.: 14-05207-EF-1.
- Kashkin V., Fedorova O., Bagrov A. et al. Endogenous sodium pump inhibitors, diabetes mellitus and preeclampsia. preliminary observations and a hypothesis // Pathophysiology. – 2007; 14 (3–4): 147–51.
- Kell D., Kenny L. A dormant microbial component in the development of preeclampsia // Front. Med. – 2016; 3: 60.
- Kim C., Romero R., Chaemsaithong P. et al. Chronic inflammation of the placenta: definition, classification, pathogenesis, and clinical significance // Am. J. Obstet. Gynecol. – 2015; 213 (4 Suppl.): 53–69.
- Krishna U., Bhalerao S. Placental insufficiency and fetal growth restriction // J. Obstet. Gynaecol. India. – 2011; 61 (5): 505–11.
- Lam G. et al. Antepartum administration of a digoxin immune Fab (Digibind®) improves renal function in patients with severe preeclampsia. Proceedings of XVI congress of International Society for the Study of Hypertension in Pregnancy. Washington DC. – 2008; 44: 60.
- LaMarca H., Morris C., Pettit G. et al. Marinobufagenin impairs first trimester cytotrophoblast differentiation // Placenta. – 2006; 27 (9–10): 984–8.
- Maharaj C., O'Toole D., Lynch T. et al. Effects and mechanisms of action of sildenafil citrate in human chorionic arteries // Reprod. Biol. Endocrinol. – 2009; 23 (7): 34.
- Mastrolia S., Novack L., Thachil J. et al. LMWH in the prevention of preeclampsia and fetal growth restriction in women without thrombophilia. A systematic review and meta-analysis // Thromb. Haemost. – 2016; 116 (5): 868–78.
- Meher S., Duley L., Hunter K. et al. Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis // Am. J. Obstet. Gynecol. – 2017; 216 (2): 121–8..
- Morton J., Cooke C., Davidge S. In Utero Origins of Hypertension: Mechanisms and Targets for Therapy // Physiol. Rev. – 2016; 96 (2): 549–603.
- Nadeau-Vallée M., Obari D., Palacios J. et al. Sterile inflammation and pregnancy complications: a review // Reproduction. – 2016; 152: 277–92.
- Ohkuchi A., Hirashima C., Takahashi K. et al. Prediction and prevention of hypertensive disorders of pregnancy // Hypertens. Res. – 2017; 40 (1): 5–14.
- Oyston C., Stanley J., Baker P. Potential targets for the treatment of preeclampsia // Expert Opin. Ther. Targets. – 2015; 19 (11): 1517–30.
- Roberge S., Nicolaides K., Demers S. et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic reviewand meta-analysis // Am. J. Obstet. Gynecol. – 2017; 216 (2): 110–20.
- Rytlewski K., Olszanecki R., Lauterbach R. et al. Effects of oral L-arginine on the foetal condition and neonatal outcome in preeclampsia: a preliminary report // Basic Clin. Pharmacol. Toxicol. – 2006; 99 (2): 146–52.
- Saleh L., Danser J., van den Meiracker A. Role of endothelin in preeclampsia and hypertension following antiangiogenesis treatment // Curr. Opin. Nephrol. Hypertens. – 2016; 25 (2): 94–9.
- Shilova V., Fedorova O., Bagrov A. et al. In preeclampsia endogenous cardiotonic steroids induce vascular fibrosis and impair relaxation of umbilical arteries // J. Hypertens. – 2011; 29 (4): 769–76.
- Thejeel B., Garg A., Clark W. et al. Long-term outcomes of thrombotic microangiopathy treated with plasma exchange: A systematic review // Am. J. Hematol. – 2016; 91 (6): 623–30.
- Townsend R., O'Brien P., Khalil A. Current best practice in the management of hypertensive disorders in pregnancy // Integr. Blood Press Control. – 2016; 9: 79–94.
- Visser S., Hermes W., Ket J. et al. Systematic review and metaanalysis on nonclassic cardiovascular biomarkers after hypertensive pregnancy disorders // Am. J. Obstet. Gynecol. – 2014; 211: 373.
- von Dadelszen P., Magee L. Preventing deaths due to the hypertensive disorders of pregnancy // Best Pract. Res. Clin. Obstet. Gynaecol. – 2016; 36: 83–102